A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910